New patient trials surrounding this compound, specifically the 120 milligram formulation ZPHC ZPHC, indicate a significant effect on weight loss and related metabolic factors. Scientists anticipate that this combined agonist , targeting both GLP-1 and GIP pathways , could provide a major improvement in the approach of overweight and connected heal